John Montana

MatriSys is a clinical stage company that is harnessing beneficial bacteria to treat chronic inflammatory skin conditions.

Tundra has developed a bispecific antibody for cancer and has initiated a clinical study treating patients with relapsed/refractory CD30+ leukemias or lymphomas.

Resolute Science, Inc. is a San Diego-based preclinical-stage biotech company advancing a pipeline of first-in-class, tumor-agnostic, targeted cytotoxic, and radiopharmaceutical therapeutics for solid tumors. Its mission is to bring effective and well-tolerated therapeutics to patients who have run out of options.

Arpeggio is developing the world's fastest platform for transcriptomic sequencing to learn how chemistry maps to network biology; and working on developing a pipeline of potential drugs to tackle drug resistance in cancer, chronic kidney disease, and neurodegeneration.

NuFund Venture Group is a leader among angel investors and the innovative force behind a unique fund model targeting emerging technology leaders. NuFund’s greatest strength is their vast and deep bench of subject matter expert (SME) members who not only help identify the best deals, but also help the founders NuFund invests in to succeed on the entrepreneurial journey,

Supporting Life Science organizations through proven Project Management/Leadership tools and techniques to maximize resource efficiency. Technical expert with ability to streamline preclinical/clinical activities helping companies achieve project milestones within budget and timeline constraints. Experienced in Alliance Management and performing due diligence assessments for large and small companies.

Founding member of a company focused on generating proof-of-concept data for a lead compound in an orphan-dermatology indication. Primary responsibilities included management of all outsourced R&D activities, including preclinical pharm/tox studies, formulation development, CTM and clinical operations. Responsible to CEO and Board for delivering the program within time, cost and quality expectations.

Strategic leader and member of site Executive Team. Accountable for leadership and management of local portfolio governance and execution-level teams. Maintained key interactions with wider AstraZeneca organization. Supported functional teams in the successful NDA and MAA submissions for Zurampic and Duzallo (treatment for patients with gout). Managed Project Management, Finance, Accounting and Procurement functions, ensuring delivery of fiscal reports and analyses to global organization and partners. Oversaw all internal Clinical Operations functions supporting project deliverables. Worked closely with external contract organizations during all phases of partnership, including bid defense, contract definition, program execution, risk mitigation and closure.

Established new PMO structure to help deliver projects more efficiently. Responsible for Project Leadership, Project Management, Strategic Planning and Alliances.

Established PMO system into organization to better-manage growing portfolio of products.

Member of Senior Management Team, responsible for daily operations of R&D portfolio and generating strategic direction for organization. Integrated a new Project Management/Project Team structure into the organization. Developed strategic options for the portfolio and projects, based on risk/reward and downstream implications. Primary contact with co-development partners (LGLS and Novartis) on two lead compounds targeted at HBV and HCV. Lead member of due diligence team, communicating directly with potential partner organizations. Managed all home-grown projects in development portfolio, including alliance management and contract organizations across preclinical, CMC and clinical functions.